Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota - Archive ouverte HAL Access content directly
Journal Articles OncoImmunology Year : 2017

Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota

Abstract

Although anticancer therapy with immune checkpoint blockers has seen unprecedented success, it fails to control neoplasia in most patients and often causes immune-related adverse events (irAEs). Our recent research shows the immunostimulatory and antitumor effects of CTLA-4 blockade depend on distinct Bacteroides species of the gut microbiota, signifying novel approaches to improve such immunotherapies.

Dates and versions

hal-01602605 , version 1 (02-10-2017)

Identifiers

Cite

Jonathan M. Pitt, Marie Vetizou, Ivo Gomperts Boneca, Patricia Lepage, Mathias Chamaillard, et al.. Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. OncoImmunology, 2017, 6 (1), ⟨10.1080/2162402X.2015.1132137⟩. ⟨hal-01602605⟩
261 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More